NEW YORK (GenomeWeb News) - Epigenomics will use its differential methylation hybridization chip to help Johnson & Johnson Pharmaceutical Research & Development identify and analyze biomarkers for potential cancer drugs.
Terms of the agreement call for Epigenomics to receive an undisclosed upfront payment under the agreement.
Additional financial details were not disclosed.